Catherinn BV

Catherinn BV (Cancer Therapeutics and Innovation) is a virtual research and development company devoted to the improvement of diagnostic and treatment options for Small Cell Lung Cancer (SCLC) patients. Catherinn was started by a group of highly motivated experts and entrepreneurs in the life science and vaccine industry. Important work on SCLC diagnostics and therapy was carried out and patented by the group of prof. Frans Ramaekers, department of molecular cell biology of the Maastricht University Medical Center. In 2014, the patent was acquired by Catherinn BV. We are committed to improving the lives of SCLC cancer patients, both by prevention through early screening and by cure through immunotherapy.